On July 14, ImmunityBio declined 5.17% in regular trading, trading at $7.805/share, with turnover of $44.70 million.

On the news front, the U.S. biotech sector experienced concentrated profit-taking after accumulating approximately 25% gains over the past month. The high-beta representative ETF (XBI) previously dropped 4% in a single session, with capital rotating structurally from high-risk small-cap biotech names toward large-cap defensive pharmaceutical companies. ImmunityBio, as a small-cap biotech stock with significant year-to-date gains, continued its pullback absent any fundamental negative catalysts.

ImmunityBio is a comprehensive immunotherapy company whose core product Anktiva has been approved in 33 countries for bladder cancer and lung cancer treatment. The company reported Q1 net product revenue of $44.2 million, representing approximately 168% year-over-year growth, with cash and marketable securities totaling $381 million as of quarter-end.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)